GSK announces core EPS of 112.2p and dividend of 78p
- Core EPS of 112.2p (+4% CER) and dividend of 78p (+5%)
- £5.2 billion of cash returned to shareholders through 5% increase in 2013 dividend to 78p, (Q4 23p) and repurchase of £1.5 billion of shares
- Exceptional year for R&D delivery with approvals for six major products and five additional regulatory filings completed
- New product launches strengthen businesses in Respiratory, Vaccines, HIV and Oncology
Pipeline opportunity remains substantial with Phase III data for six potential new drugs and vaccines and around ten NME Phase III starts across 2014 and 2015.
More details with CEO and CFO interview available in the quarterly results section of this website.